NDAORALTABLETPriority Review
Approved
Jul 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
Priority Review
EFFIENT (prasugrel hydrochloride) by Molecular Devices is p2y 12 class of adp receptors on platelets. First approved in 2009.
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EFFIENT (prasugrel hydrochloride) is an oral P2Y12 ADP receptor antagonist antiplatelet agent approved in 2009 for acute coronary syndromes. It reduces platelet aggregation to prevent thrombotic cardiovascular events in patients undergoing percutaneous coronary intervention (PCI). The drug is administered as an oral tablet and represents a second-generation thienopyridine with faster onset and greater potency than clopidogrel.
$0.039BPart D
LOE ApproachingDeclining
With LOE approaching and minimal Part D spending ($39K in 2023), the brand team is likely consolidating and focusing on managed decline strategies rather than growth initiatives.
Mechanism of Action
P2Y 12 class of ADP receptors on platelets.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
EFFIENT offers limited career growth due to approaching LOE, minimal market activity (42 claims, $39K Part D spending in 2023), and zero linked job openings. Roles on this product are primarily defensive, focused on managed decline, market access negotiation, and generic transition planning rather than expansion or innovation.
Brand ManagerMedical Science Liaison
Worked on EFFIENT at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.